FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163965708> ?p ?o ?g. }

• W3163965708 endingPage "422" @default.
• W3163965708 startingPage "409" @default.
• W3163965708 abstract "Chemotherapy has been widely used for treating the vast majority of cancer patients. Unfortunately, only a fraction of patients can respond to chemotherapies, but these patients still experience severe side effects. In this context, a wide range of nanotherapeutic platforms have been developed with the aim of improving treatment outcomes while reducing drug toxicities. Nanohydrogels are highly appealing “smart” biocompatible and biodegradable vehicles for either local or systemic delivery of bioactive compounds. Here, we developed prodrug hydrogelators that can undergo one-step distillation-precipitation polymerization to form systemically injectable nanohydrogels. The optimized nanohydrogels were capable of rapidly releasing active agents (e.g., the cytotoxic agent cabazitaxel or the PI3K molecular inhibitor PI103) in response to the reducing tumor microenvironment, while drug release was very slow in the absence of the reductive reagent glutathione. Cabazitaxel-loaded nanogels showed preferential tumor accumulation, and administration of nanogels produced durable tumor regression in a docetaxel-resistant cervical tumor xenograft-bearing mouse model. More significantly, nanogel-based therapy was proven to demonstrate a higher safety profile than solution-based free cabazitaxel. Collectively, this study provides an alternative formulation that meets the essential requirements of high stability in the blood, spontaneous drug release at diseased sites, favorable safety in vivo, and translational capacity for further investigations. Chemotherapy remains a considerable challenge and only a fraction of patients can respond to chemotherapies. Here we report an intratumoral reducing agent-activatable, tumor-targeting prodrug nanogel platform for therapeutic delivery. To this end, two anticancer agents (e.g., cytotoxic cabazitaxel or PI3K molecular inhibitor PI103) are tested. Prodrug nanogels are stable in the blood but performed reduction-triggered release of chemically unmodified drug molecules in cancerous tissues. Cabazitaxel-loaded nanogels exhibit satisfactory anticancer performance in a preclinical docetaxel-resistant tumor model. This is a practical and expedient approach that combines the prodrug strategy and nanogel scaffold to re-engineer a hydrophobic and toxic anticancer drug. The approach also is broadly applicable for the formulation of other agents to improve the therapeutic index." @default.
• W3163965708 created "2021-06-07" @default.
• W3163965708 creator A5019491326 @default.
• W3163965708 creator A5028742166 @default.
• W3163965708 creator A5035375708 @default.
• W3163965708 creator A5037649298 @default.
• W3163965708 creator A5037668780 @default.
• W3163965708 creator A5042036838 @default.
• W3163965708 date "2021-08-01" @default.
• W3163965708 modified "2023-10-17" @default.
• W3163965708 title "A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies" @default.
• W3163965708 cites W1539469412 @default.
• W3163965708 cites W1765690317 @default.
• W3163965708 cites W1835542131 @default.
• W3163965708 cites W1948389446 @default.
• W3163965708 cites W1966090623 @default.
• W3163965708 cites W1968415110 @default.
• W3163965708 cites W1986246906 @default.
• W3163965708 cites W1989230986 @default.
• W3163965708 cites W1990806983 @default.
• W3163965708 cites W1996186923 @default.
• W3163965708 cites W2006371280 @default.
• W3163965708 cites W2030897628 @default.
• W3163965708 cites W2032860131 @default.
• W3163965708 cites W2040737049 @default.
• W3163965708 cites W2043998312 @default.
• W3163965708 cites W2069897834 @default.
• W3163965708 cites W2071756286 @default.
• W3163965708 cites W2075277486 @default.
• W3163965708 cites W2076661203 @default.
• W3163965708 cites W2083350623 @default.
• W3163965708 cites W2091796668 @default.
• W3163965708 cites W2102449174 @default.
• W3163965708 cites W2141395077 @default.
• W3163965708 cites W2147417654 @default.
• W3163965708 cites W2148703012 @default.
• W3163965708 cites W2253277805 @default.
• W3163965708 cites W2414230095 @default.
• W3163965708 cites W2460068665 @default.
• W3163965708 cites W2513717750 @default.
• W3163965708 cites W2558862288 @default.
• W3163965708 cites W2568159634 @default.
• W3163965708 cites W2580784198 @default.
• W3163965708 cites W2625658222 @default.
• W3163965708 cites W2730071659 @default.
• W3163965708 cites W2735519026 @default.
• W3163965708 cites W2766551075 @default.
• W3163965708 cites W2769964316 @default.
• W3163965708 cites W2783535867 @default.
• W3163965708 cites W2889646458 @default.
• W3163965708 cites W2900242251 @default.
• W3163965708 cites W2901337024 @default.
• W3163965708 cites W2902946041 @default.
• W3163965708 cites W2909844146 @default.
• W3163965708 cites W2946216397 @default.
• W3163965708 cites W2946248080 @default.
• W3163965708 cites W2954726610 @default.
• W3163965708 cites W2960482396 @default.
• W3163965708 cites W2960509435 @default.
• W3163965708 cites W2986097069 @default.
• W3163965708 cites W2993896964 @default.
• W3163965708 cites W2994196492 @default.
• W3163965708 cites W2994679067 @default.
• W3163965708 cites W2995946125 @default.
• W3163965708 cites W3007181851 @default.
• W3163965708 cites W3028033503 @default.
• W3163965708 cites W3032914086 @default.
• W3163965708 cites W3036718711 @default.
• W3163965708 cites W3049666647 @default.
• W3163965708 cites W3137707194 @default.
• W3163965708 cites W4240930123 @default.
• W3163965708 doi "https://doi.org/10.1016/j.actbio.2021.05.047" @default.
• W3163965708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34087447" @default.
• W3163965708 hasPublicationYear "2021" @default.
• W3163965708 type Work @default.
• W3163965708 sameAs 3163965708 @default.
• W3163965708 citedByCount "8" @default.
• W3163965708 countsByYear W31639657082021 @default.
• W3163965708 countsByYear W31639657082022 @default.
• W3163965708 countsByYear W31639657082023 @default.
• W3163965708 crossrefType "journal-article" @default.
• W3163965708 hasAuthorship W3163965708A5019491326 @default.
• W3163965708 hasAuthorship W3163965708A5028742166 @default.
• W3163965708 hasAuthorship W3163965708A5035375708 @default.
• W3163965708 hasAuthorship W3163965708A5037649298 @default.
• W3163965708 hasAuthorship W3163965708A5037668780 @default.
• W3163965708 hasAuthorship W3163965708A5042036838 @default.
• W3163965708 hasConcept C108215921 @default.
• W3163965708 hasConcept C121608353 @default.
• W3163965708 hasConcept C126322002 @default.
• W3163965708 hasConcept C134424308 @default.
• W3163965708 hasConcept C141071460 @default.
• W3163965708 hasConcept C151730666 @default.
• W3163965708 hasConcept C171250308 @default.
• W3163965708 hasConcept C192562407 @default.
• W3163965708 hasConcept C2776694085 @default.
• W3163965708 hasConcept C2777292972 @default.
• W3163965708 hasConcept C2777511904 @default.

• next